CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC (CELZ)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.04-3.70%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Net losses reduce toward breakeven: EPS metric not reported.
Creative Medical Technology focuses on adult stem cell treatments in several medical fields. The company aims to stabilize its business despite current losses. Its recent capital raises provide runway to advance its therapies. If it can halt revenue decline, it may recover value.
The company is losing money and analysts expect revenue to drop about 60% next year. Recent equity sales dilute shareholders and signal funding needs. The sharp stock selloff reflects high risk and uncertain recovery. Continued losses could worsen the situation.
The stock trades about 30% below our valuation model's level. Analysts expect revenue to fall roughly 60% next year, reflecting a weak outlook. Our view is cautious given the company's losses and uncertain growth prospects.
Breaks if: capital runway falls below 6 months
Breaks if: EPS remains below -$0.5 over next 4 quarters
Breaks if: revenue decline worsens beyond -10% YoY over next 4 quarters
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
CELZ represents a speculative growth investment with a high-risk profile. The current thesis state reflects concerns over its financial performance and management's ability to stabilize cash flow.
The market appears to have low expectations for CELZ, as indicated by its premium valuation compared to peers. This suggests that investors may not be fully pricing in the potential for continued operating losses and cash flow challenges.
Fundamentals are likely to remain under pressure due to persistent operating losses and negative cash flow. Management's focus on cash management and capital allocation is a newly initiated priority, but it remains to be seen how effective these measures will be.
The long-term thesis hinges on broader healthcare sector performance, particularly the results of major companies like VRTX, REGN, and ARGX. Additionally, the potential for an earnings miss in the near term poses a significant risk.
In the next 1 to 3 years, CELZ's outlook will depend heavily on its ability to manage losses and the overall health of the healthcare sector. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.